பிரியாணி ரினி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from பிரியாணி ரினி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In பிரியாணி ரினி Today - Breaking & Trending Today
UroToday - The Global Online Community of Urologists urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
SHARE ASCO GU 2021: TIVO-3: Tivozanib in Patients with Advanced Renal Cell Carcinoma Who Have Progressed After Treatment with Axitinib Published 14 February 2021 (UroToday.com) Tivozanib is a potent and highly selective VEGF receptor tyrosine kinase inhibitor in clinical development for renal cell carcinoma (RCC). Axitinib is also a potent and selective VEGF-receptor inhibitor now commonly part of front-line advanced RCC treatment. In the TIVO-3 trial, tivozanib demonstrated significantly greater progression-free survival (PFS) (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56-0.94) and objective response rate (ORR) (15.2% versus 7.5%, p=0.003) versus sorafenib in the intention to treat population, in the subset of patients treated with two prior VEGFR-tyrosine kinase inhibitors (TKI), and in patients treated with a prior VEGFR-TKI and an anti-PD-1 antibody. ....